PRRG2 Activators
PRRG2 activators constitute a diverse array of small molecules that can modulate the activity of PRRG2, a protein with multifaceted roles in cellular processes. Gefitinib, an EGFR inhibitor, emerges as a noteworthy PRRG2 activator by targeting the EGFR signaling pathway. By inhibiting EGFR, Gefitinib indirectly activates PRRG2, preventing its downregulation and sustaining cellular processes influenced by PRRG2 through modulation of the EGFR cascade. Similarly, SB203580, an inhibitor of p38 MAPK, and Axitinib, a VEGFR inhibitor, contribute to PRRG2 activation by impeding the respective pathways. SB203580 prevents PRRG2 downregulation, influencing cellular processes through the inhibition of p38 MAPK, while Axitinib fosters sustained PRRG2 activity by suppressing VEGFR signaling.
AZD6244, a MEK inhibitor, represents another facet of PRRG2 activation. Through its influence on the MAPK/ERK pathway, AZD6244 prevents PRRG2 downregulation, contributing to the sustained activity of PRRG2 and its impact on cellular processes linked to MAPK/ERK signaling. Tofacitinib, Imatinib, LY294002, Selumetinib, Dasatinib, Bosutinib, BAY 61-3606, PHA-665752, and Dasatinib contribute to PRRG2 activation by targeting JAK/STAT, BCR-ABL, PI3K/AKT, MEK, Src, Src/Abl, Syk, and c-Met signaling pathways, respectively. These compounds showcase the versatility of PRRG2 regulation and its involvement in diverse cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, indirectly activates PRRG2 by suppressing the EGFR signaling pathway. This inhibition prevents PRRG2 downregulation, fostering sustained PRRG2 activity and influencing cellular processes related to PRRG2 through modulation of the EGFR signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly activates PRRG2 by inhibiting the p38 MAPK pathway. This inhibition prevents PRRG2 downregulation, promoting sustained PRRG2 activity. The compound influences cellular processes related to PRRG2 through modulation of the p38 MAPK signaling cascade. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a BCR-ABL tyrosine kinase inhibitor, indirectly activates PRRG2 by suppressing the BCR-ABL signaling pathway. This inhibition prevents PRRG2 downregulation, fostering sustained PRRG2 activity and influencing cellular processes related to PRRG2 through modulation of the BCR-ABL signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates PRRG2 by suppressing the PI3K/AKT pathway. This inhibition prevents PRRG2 downregulation, promoting sustained PRRG2 activity. The compound influences cellular processes related to PRRG2 through modulation of the PI3K/AKT signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, indirectly activates PRRG2 by suppressing the Src signaling pathway. This inhibition prevents PRRG2 downregulation, fostering sustained PRRG2 activity and influencing cellular processes related to PRRG2 through modulation of the Src signaling cascade. | ||||||
PHA 665752 | 477575-56-7 | sc-203186 sc-203186A sc-203186B sc-203186C | 2 mg 10 mg 50 mg 200 mg | $143.00 $281.00 $714.00 $1510.00 | 24 | |
PHA-665752, a c-Met inhibitor, indirectly activates PRRG2 by suppressing the c-Met signaling pathway. This inhibition prevents PRRG2 downregulation, fostering sustained PRRG2 activity and influencing cellular processes related to PRRG2 through modulation of the c-Met signaling cascade. | ||||||